Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...
The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
Rita Mukhtar, MD, breast oncologic surgeon, affiliate professor of surgical procedure, Division of Surgical Oncology, Lobular Breast Most cancers Program, College of California,...
On this video, Kelly L. Stratton, MD, FACS, discusses a noteworthy side of a section 1B trial evaluating relugolix (Orgovyx) and enzalutamide (Xtandi)...
